[{"id":"8c71eabb-cd74-4759-82b6-0d000c43a43f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04571892","created_at":"2021-01-18T21:49:50.079Z","updated_at":"2024-07-02T16:35:50.835Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors","source_id_and_acronym":"NCT04571892","lead_sponsor":"Shanghai East Hospital","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ScTIL210"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-12"},{"id":"5b7aca1a-24f8-4440-bac3-cb40edc7fa7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730361","created_at":"2023-02-15T18:03:22.791Z","updated_at":"2024-07-02T16:35:55.454Z","phase":"Phase 1","brief_title":"Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors","source_id_and_acronym":"NCT05730361","lead_sponsor":"Peking University","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ScTIL210"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-02-15"}]